ClinicalTrials.gg
RecruitingNCT05884255Updated May 19, 2026

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

A Phase 3 interventional study of Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide and long-acting Octreotide in Advanced Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.

02

Conditions studied

  • Advanced Gastroenteropancreatic Neuroendocrine Tumor
03

In context

Gastro-enteropancreatic neuroendocrine tumor

73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.

This study's planned enrollment of 220 is above the median of 53 across 49 interventional studies indexed under Gastro-enteropancreatic neuroendocrine tumor.

Browse Gastro-enteropancreatic neuroendocrine tumor studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written ;
  2. 18\~75 years old,male or female;
  3. performance status 0 or 1;
  4. Unresectable locally advanced or gastrointestinal neuroendocrine tumors (GEP-NETs) of low and medium grade (G1 or G2) confirmed by histopathology.

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system is known. Patients who have previously received treatment ( radiotherapy or surgery ) for and have no clinical symptoms can be enrolled if the pre-randomized pre-imaging is confirmed to be stable for at least 24 weeks;
  2. There are clinical symptoms or diseases of the heart that are not well controlled;
  3. Diabetes (fasting blood glucose > 2 × ) that cannot be well controlled after optimal medical support treatment;
  4. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction or indwelling catheter for any reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    Drug: Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide

  • Active comparator
    Treatment group B

    Drug: long-acting Octreotide

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by BICR

    Time frame: Up to 1 year follow-up

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 5 years follow-up

  2. Objective Response Rate (ORR)

    Time frame: up to 1 year follow-up

  3. Duration of Overall Response (DoR)

    Time frame: Up to 1 year follow-up

  4. Disease Control Rate (DCR)

    Time frame: Up to 1 year follow-up

  5. Incidence and severity of adverse event (AE) and serious adverse event (SAE)

    Time frame: Up to 5 years follow-up

07

Study locations

2 of 2 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 201321, China
    Recruiting
  • Tianjin University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Jihui Hao · Contactherenrh@163.com · 022-23353454
    • Jihui Hao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jun 1, 2023
StartActual
Jul 6, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Oct 2030
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05884255
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Jul 6, 2023
Primary completion
Dec 2026 (estimated)
Completion
Oct 2030 (estimated)
Last update
May 19, 2026

Study contacts

Xueying Zheng
Contact
xueying.zheng.xz17@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion